Letter: Pathogenicity of Th17 cells may differ in ulcerative colitis compared with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 2, 2012, Pages 204-

  Raza, A ^a   Shata, M T ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; LIPOPOLYSACCHARIDE;

CLINICAL ASSESSMENT TOOL; COMPARATIVE STUDY; CORRELATION COEFFICIENT; CROHN DISEASE; DRUG TREATMENT FAILURE; HARVEY BRADSHAW INDEX; HUMAN; IMMUNOPATHOGENESIS; LETTER; PATHOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASTICITY; PRIORITY JOURNAL; TH17 CELL; ULCERATIVE COLITIS;

CD4-POSITIVE T-LYMPHOCYTES; CROHN DISEASE; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-17; INTESTINAL MUCOSA; MALE; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84862556132     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05124.x     Document Type: Letter

References (4)

1. Veny M, Esteller M, Ricart E, et al,. Late Crohn's disease patients present an Increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther 2010; 31: 561-72.
2. Hueber W, Dhavalkumar DP, Thaddeus D, et al,. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Trans Med 2010; 2: 52ra72.
3. Hueber W, Sands BE, Vandemeullebroecke M, et al,. Inhibition of interleukin- 17A by secukinumab is ineffective for Crohn's disease (CD). J Crohns Colitis 2011; 5: S7.
4. Raza A, Ahmed K, Navaneethan U, et al,. The levels of IL-17 secreted by Lipopolysaccharide-stimulated Peripheral Blood Mononuclear Cells (PBMC) in Inflammatory Bowel Disease (IBD) patients significantly correlated with disease severity in Ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 2011; 2s: S486.